An investor consortium led a $351m Series D round in Eikon Therapeutics.

An investor consortium led a $351m Series D round in Eikon Therapeutics, a pivotal-stage biotechnology company, with participation from Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, T. Rowe Price Associates and UC Investments. “This financing provides the resources necessary to build a fully-integrated, 21st-century biotechnology company that leverages advanced computing, data sciences, and decades of experience in bringing innovative medicines to patients. The continued support of our world-class syndicate of investors is a testament both to the progress we have already made, and to the confidence of investors in our ability to deliver important new medicines for the world,” Roger M. Perlmutter, Eikon Therapeutics CEO and Board Chair.